Attorneys for the government and drug manufacturer Eli Lilly dueled over the legality of 340B contract pharmacy requirements during a hearing before a federal district judge in Indianapolis today.
Stakeholders are watching the Lilly case closely because, given how far
…
An influential Republican congressman on Monday cautioned against amending federal spending legislation to rebuke six drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.
During a July 26 U.S. House Rules Committee hearing, Rep. Michael Burgess (R-Texas)
…
AstraZeneca and the federal government have filed a new round of briefs in the drug manufacturer’s 340B contract pharmacy lawsuit, this round focused on the government’s May 17 letter telling the company its contract pharmacy actions are illegal.
In a
…
The 340B program “will not be overlooked” if the drug industry strikes a grand bargain with Congress and the Biden administration on lowering drug prices, biopharma policy analyst Michael McCaughan predicted this week during a talk on drug pricing reform
…
Drug manufacturer Novo Nordisk is giving 340B covered entities refunds for overcharges on two package sizes of its Tresiba FlexTouch insulin pen and on 10 milliliter vials of its Fiasp brand insulin.
The U.S. Health Resources and Services Administration (HRSA)
…
Drug industry vendor Kalderos is urging leaders in Washington to temporarily shield hospitals from losing their 340B eligibility during the COVID-19 pandemic.
“Kalderos is urging a rapid federal response to protect these hospitals,” the company said in a July 23
…
Retired U.S. Sen. Mike Enzi (R-Wy.), who co-led inquiries into stewardship of the 340B program while in Congress, died on Monday after being injured in a bicycle accident in his hometown of Gillette, Wyo. He was 77.
Enzi was a
…SPONSORED CONTENT
Finance guys like myself often have the reputation of being unwilling to spend money. However, we can always be convinced to invest in activities with a high likelihood of return.
The financial pressures of the last year have underscored the importance of the 340B program and its impact on hospital finances. Against the backdrop
…
The U.S. House voted this evening “to highlight the need to protect the integrity of the 340B program by halting pharmaceutical manufacturers’ unlawful actions that have resulted in overcharges to 340B covered entities.”
Reps. Abigail Spanberger (D-Va.) and David McKinley
…
UPDATE Tuesday, July 27, 2021, 1:45 p.m. Eastern—Drug manufacturer Novartis provided the following statement:
“Novartis recently notified the Health Resources and Services Administration (HRSA) that we inadvertently neglected to offer the 340B ceiling price to covered entity types added by
…*Sign up for news summaries and alerts from 340B Report
